Isomorphic Labs reportedly seeks $5bn in funding at a $50bn valuation

Business · First reported 4 Nov, 22:51 · Updated 22:22

Image: Wikimedia Commons · NASA Johnson Space Center / Jonny Kim · Public domain

Isomorphic Labs is reportedly discussing a $5bn funding round at a valuation of about $50bn, but the financing has not closed and its terms could change. The company’s drug-development work remains preclinical, with its first clinical trials expected by the end of 2026, according to the supplied reports.

Isomorphic Labs is in talks to raise about $5bn at a valuation of around $50bn; the financing is not final and terms may change.
The company spun out of Google DeepMind in 2021 and is developing AI tools for drug discovery, building on the AlphaFold protein-structure model.
Its work is still in preclinical stages. Demis Hassabis said the company expected to begin its first clinical trials by the end of 2026.
The reports describe a May funding round of $2.1bn, led by Thrive Capital, with Alphabet among the investors.
Isomorphic is among companies applying AI to medicine; the reports also name OpenAI and Chai Discovery in the field.

Summary written by Lux AI from 3 articles

Key facts

Proposed funding: About $5bn; talks are ongoing and the financing has not closed.
Reported valuation: About $50bn.
Company origin: Spun out of Google DeepMind in 2021.
Development stage: Drug work described as preclinical.
Expected first clinical trials: By the end of 2026, according to the report.